Correlation of PIM kinases with tumor immune microenvironment and clinical presentation of metastatic hormone-sensitive prostate cancer.

被引：0
|
作者：
Recio-Boiles, Alejandro
Clements, Amber N.
Deshmukh, Sachin Kumar
Bertolo, Aaron
Estrada-Mendizabal, Ricardo J.
Saboda, Kathylynn
Wu, Sharon
Xiu, Joanne
Radovich, Milan
Sutterby, Kai
Chauhan, Shailender S.
McKay, Rana R.
Nabhan, Chadi
Warfel, Noel A.
机构：
[1] Univ Arizona, Canc Ctr, Tucson, AZ USA
[2] Caris Life Sci, Phoenix, AZ USA
[3] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey, Mexico
[4] Univ Calif San Diego, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [31] Systemic therapy in metastatic hormone-sensitive prostate cancer
    McDonald, Jodie
    O'Brien, Jonathan
    Kostos, Louise
    Lawrentschuk, Nathan
    Azad, Arun A.
    Murphy, Declan
    Chen, Kenneth
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2022, 16 (04) : 234 - 239
  • [32] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [33] The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).
    Yuen, Kobe Chi Yung
    Ben Tran
    Gibbs, Peter
    Anton, Angelyn
    Mariathasan, Sanjeev
    Sandhu, Shahneen Kaur
    Kadel, Edward Ernest
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Number of prescription medications and overall survival in veterans with metastatic hormone-sensitive prostate cancer.
    Karunanandaa, Krishny
    Pickett, Carley
    Eaton, Daniel B.
    Tohmasi, Steven
    Ingram, Kara
    Gopukumar, Deepika
    Puri, Varun
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 68 - 68
  • [35] Treatment of primary cancer in metastatic hormone-sensitive prostate cancer
    Lim, Kylie Y. -Y.
    Alberto, Matthew
    Ranasinghe, Weranja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (04) : 315 - 323
  • [36] Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials
    Dzimitrowicz, Hannah E.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (08) : 807 - +
  • [37] Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy
    Chakrabarti, Deep
    Parker, Chris C.
    EUROPEAN UROLOGY, 2024, 86 (01) : 18 - 19
  • [38] Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer
    Naito, Yushi
    Kato, Masashi
    Kawanishi, Hideji
    Yamamoto, Akiyuki
    Sakamoto, Fumitoshi
    Hirabayashi, Hiroki
    Kobayashi, Masataka
    Matsukawa, Yoshihisa
    Kimura, Tohru
    Araki, Hidemori
    Nishikimi, Toshinori
    Kondo, Atsuya
    Yoshino, Yasushi
    Hashimoto, Yoshimasa
    Nakano, Yojiro
    Tsuzuki, Toyonori
    PROSTATE, 2023, 83 (04): : 307 - 315
  • [39] The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone-sensitive prostate cancer.
    Shaya, Justin
    Lee, Aaron
    Cabal, Angelo
    Panian, Justine
    Randall, James Michael
    Millard, Frederick E.
    Stewart, Tyler Francis
    Rose, Brent S.
    Parsons, John Kellogg
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
    Kwan, Edmond M.
    Azad, Arun A.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 617 - 619
12345